{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T23:39:50Z","timestamp":1792539590788,"version":"4.5.0"},"reference-count":35,"publisher":"Oxford University Press (OUP)","issue":"6","license":[{"start":{"date-parts":[[2024,3,12]],"date-time":"2024-03-12T00:00:00Z","timestamp":1710201600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Novartis Pharma AG"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,5,16]]},"abstract":"<jats:title>Lay Summary<\/jats:title>\n               <jats:p>Hidradenitis suppurativa (HS) is a chronic skin disease that causes painful boils. HS is common and affects about 0.4% of the world\u2019s population. Treating the condition is difficult, but drugs called \u2018biologics\u2019 can help to improve the symptoms. For example, secukinumab is a biologic drug that has been shown to be effective and well-tolerated for the treatment of HS.<\/jats:p>\n               <jats:p>In this analysis, we investigated whether previous treatment with biologics could affect the effectiveness and tolerability of secukinumab. This analysis included data from two identical clinical trials (called SUNSHINE and SUNRISE) that recruited adult patients with HS who had moderate-to-severe disease. In these trials, patients took secukinumab 300\u2005mg every 2 weeks or every 4 weeks for 1\u2005year, or a placebo for 4\u2005months and then switched to secukinumab until 1\u2005year. At regular intervals, the effectiveness and tolerability of secukinumab were examined and the results were compared between patients who had previously used another biologic and patients who had never used a biologic before.<\/jats:p>\n               <jats:p>After 16 weeks, patients who took secukinumab had better results than the patients who took a placebo, independent of previous biologic use. Secukinumab was still effective and had improved results over 1\u2005year of treatment in both subgroups. Regardless of whether patients had previously been taking another biologic, secukinumab was just as tolerable as placebo and there were no new safety risks.<\/jats:p>\n               <jats:p>Our analysis shows that secukinumab is effective and tolerable, regardless of whether patients have previously used another biologic drug.<\/jats:p>","DOI":"10.1093\/bjd\/ljae098","type":"journal-article","created":{"date-parts":[[2024,3,12]],"date-time":"2024-03-12T13:07:00Z","timestamp":1710248820000},"page":"836-845","source":"Crossref","is-referenced-by-count":33,"title":["Secukinumab in patients with moderate-to-severe hidradenitis suppurativa based on prior biologic exposure: an efficacy and safety analysis from the SUNSHINE and\u00a0SUNRISE phase III trials"],"prefix":"10.1093","volume":"190","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1646-2608","authenticated-orcid":false,"given":"Christos C","family":"Zouboulis","sequence":"first","affiliation":[{"name":"Departments of Dermatology, Venereology, Allergology and Immunology, Staedtisches Klinikum Dessau, Brandenburg Medical School Theodor Fontane and Faculty of Health Sciences Brandenburg , Dessau ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thierry","family":"Passeron","sequence":"additional","affiliation":[{"name":"Department of Dermatology , CHU Nice"},{"name":"INSERM U1065, C3M, C\u00f4te d\u2019Azur University , Nice ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Pariser","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Eastern Virginia Medical School , Norfolk, VA ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Magdalena B","family":"Wozniak","sequence":"additional","affiliation":[{"name":"Novartis Ireland Ltd , Dublin ,","place":["Ireland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xianjun","family":"Li","sequence":"additional","affiliation":[{"name":"Novartis Pharma Co., Ltd , Shanghai ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lorenz","family":"Uhlmann","sequence":"additional","affiliation":[{"name":"Novartis Pharma AG , Basel ,","place":["Switzerland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iryna","family":"Lobach","sequence":"additional","affiliation":[{"name":"Novartis Pharma AG , Basel ,","place":["Switzerland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angela Llobet","family":"Martinez","sequence":"additional","affiliation":[{"name":"Novartis Pharma AG , Basel ,","place":["Switzerland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shoba","family":"Ravichandran","sequence":"additional","affiliation":[{"name":"Novartis Pharmaceuticals Corporation , East Hanover, NJ ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ivette","family":"Alarcon","sequence":"additional","affiliation":[{"name":"Novartis Pharma AG , Basel ,","place":["Switzerland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annamaria","family":"Offidani","sequence":"additional","affiliation":[{"name":"Unit of Dermatology, Department of Clinical and Molecular Sciences, Polytechnic Marche University , Ancona ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maryam S","family":"Alam","sequence":"additional","affiliation":[{"name":"Simcoderm Medical and Surgical Dermatology Centre , Barrie, ON ,","place":["Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pedro","family":"Mendes-Bastos","sequence":"additional","affiliation":[{"name":"Dermatology Centre, Hospital CUF Descobertas , Lisboa ,","place":["Portugal"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2024,3,12]]},"reference":[{"key":"2024102219121223200_ljae098-B1","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.1111\/exd.14214","article-title":"What causes hidradenitis suppurativa?\u00a0\u2013 15 years after","volume":"29","author":"Zouboulis","year":"2020","journal-title":"Exp Dermatol"},{"key":"2024102219121223200_ljae098-B2","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1007\/s11916-017-0647-3","article-title":"Pain, psychological comorbidities, disability, and impaired quality of life in hidradenitis suppurativa","volume":"21","author":"Patel","year":"2017","journal-title":"Curr Pain Headache Rep"},{"key":"2024102219121223200_ljae098-B3","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1016\/j.jaad.2009.09.021","article-title":"Hidradenitis suppurativa markedly decreases quality of life and professional activity","volume":"62","author":"Matusiak","year":"2010","journal-title":"J Am Acad Dermatol"},{"key":"2024102219121223200_ljae098-B4","doi-asserted-by":"crossref","first-page":"1546","DOI":"10.1111\/bjd.14038","article-title":"Diagnostic delay in hidradenitis suppurativa is a global problem","volume":"173","author":"Saunte","year":"2015","journal-title":"Br J Dermatol"},{"key":"2024102219121223200_ljae098-B5","doi-asserted-by":"crossref","first-page":"1597","DOI":"10.1111\/jdv.18163","article-title":"Unmet clinical needs and burden of disease in hidradenitis suppurativa: real-world experience from EU5 and US","volume":"36","author":"Ingram","year":"2022","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"2024102219121223200_ljae098-B6","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1111\/jdv.15233","article-title":"Hidradenitis suppurativa\/acne inversa: a practical framework for treatment optimization \u2013 systematic review and recommendations from the HS ALLIANCE working group","volume":"33","author":"Zouboulis","year":"2019","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"2024102219121223200_ljae098-B7","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1111\/jdv.12966","article-title":"European S1 guideline for the treatment of hidradenitis suppurativa\/acne inversa","volume":"29","author":"Zouboulis","year":"2015","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"2024102219121223200_ljae098-B8","doi-asserted-by":"crossref","first-page":"2019","DOI":"10.1001\/jama.2017.16691","article-title":"Hidradenitis suppurativa: advances in diagnosis and treatment","volume":"318","author":"Saunte","year":"2017","journal-title":"JAMA"},{"key":"2024102219121223200_ljae098-B9","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1056\/NEJMoa1504370","article-title":"Two phase 3 trials of adalimumab for hidradenitis suppurativa","volume":"375","author":"Kimball","year":"2016","journal-title":"N Engl J Med"},{"key":"2024102219121223200_ljae098-B10","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1159\/000503605","article-title":"A comparison of international management guidelines for hidradenitis suppurativa","volume":"237","author":"Hendricks","year":"2021","journal-title":"Dermatology"},{"key":"2024102219121223200_ljae098-B11","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1080\/1744666X.2016.1221762","article-title":"Adalimumab for the treatment of hidradenitis suppurativa\/acne inversa","volume":"12","author":"Zouboulis","year":"2016","journal-title":"Expert Rev Clin Immunol"},{"key":"2024102219121223200_ljae098-B12","doi-asserted-by":"crossref","first-page":"455","DOI":"10.3390\/biomedicines10020455","article-title":"Paradoxical hidradenitis suppurativa during biologic therapy, an emerging challenge: a systematic review","volume":"10","author":"Ruggiero","year":"2022","journal-title":"Biomedicines"},{"key":"2024102219121223200_ljae098-B13","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1111\/bjd.19863","article-title":"Adalimumab and infliximab survival in patients with hidradenitis suppurativa: a daily practice cohort study","volume":"185","author":"Prens","year":"2021","journal-title":"Br J Dermatol"},{"key":"2024102219121223200_ljae098-B14","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1016\/S0140-6736(23)00022-3","article-title":"Secukinumab in \u00admoderate-to-severe hidradenitis suppurativa (SUNSHINE and SUNRISE): week 16 and week 52 results of two identical, multicentre, randomised, placebo-controlled, double-blind phase 3 trials","volume":"401","author":"Kimball","year":"2023","journal-title":"Lancet"},{"key":"2024102219121223200_ljae098-B15","author":"Novartis"},{"key":"2024102219121223200_ljae098-B16","author":"Novartis"},{"key":"2024102219121223200_ljae098-B17","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1111\/j.1468-3083.2011.04325.x","article-title":"Ustekinumab in clinical practice: response depends on dose and previous treatment","volume":"26","author":"Ruiz Salas","year":"2012","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"2024102219121223200_ljae098-B18","doi-asserted-by":"crossref","DOI":"10.1177\/20406223211046685","article-title":"Impact of previous biologic use and body weight on the effectiveness of guselkumab in moderate-to-severe plaque psoriasis: a real-world practice","volume":"12","author":"Hung","year":"2021","journal-title":"Ther Adv Chronic Dis"},{"key":"2024102219121223200_ljae098-B19","doi-asserted-by":"crossref","first-page":"319","DOI":"10.2165\/11310770-000000000-00000","article-title":"Efficacy and safety of etanercept in psoriasis after switching from other treatments: an observational study","volume":"10","author":"Mazzotta","year":"2009","journal-title":"Am J Clin Dermatol"},{"key":"2024102219121223200_ljae098-B20","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1111\/jdv.18632","article-title":"Development and validation of IHS4-55, an IHS4 dichotomous outcome to assess treatment effect for hidradenitis suppurativa","volume":"37","author":"Tzellos","year":"2023","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"2024102219121223200_ljae098-B21","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1038\/s41572-020-0149-1","article-title":"Hidradenitis suppurativa","volume":"6","author":"Sabat","year":"2020","journal-title":"Nat Rev Dis Primers"},{"key":"2024102219121223200_ljae098-B22","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1111\/bjd.18983","article-title":"Evidence for a \u00ad\u2018window of opportunity\u2019 in hidradenitis suppurativa treated with adalimumab: a retrospective, real-life multicentre cohort study","volume":"184","author":"Marzano","year":"2021","journal-title":"Br J Dermatol"},{"key":"2024102219121223200_ljae098-B23","first-page":"137","article-title":"Factors related to the onset and recurrence of flares in hidradenitis suppurativa patients treated with adalimumab","volume-title":"Ital J Dermatol Venerol","author":"Caposiena Caro","year":"2022"},{"key":"2024102219121223200_ljae098-B24","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1159\/000462979","article-title":"Medical and surgical treatment of hidradenitis suppurativa: a review","volume":"3","author":"Scuderi","year":"2017","journal-title":"Skin Appendage Disord"},{"issue":"Suppl. 1","key":"2024102219121223200_ljae098-B25","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1111\/exd.14123","article-title":"Endpoints of clinical trials for hidradenitis suppurativa: proceedings of a round-table session","volume":"29","author":"Zouboulis","year":"2020","journal-title":"Exp Dermatol"},{"issue":"Suppl. 1","key":"2024102219121223200_ljae098-B26","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1111\/exd.14609","article-title":"New treatments and new assessment instruments for hidradenitis suppurativa","volume":"31","author":"van Straalen","year":"2022","journal-title":"Exp Dermatol"},{"key":"2024102219121223200_ljae098-B27","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1016\/j.jaad.2019.06.1301","article-title":"Evaluating patients\u2019 unmet needs in hidradenitis suppurativa: results from the Global Survey Of Impact and Healthcare Needs (VOICE) Project","volume":"82","author":"Garg","year":"2020","journal-title":"J Am Acad Dermatol"},{"key":"2024102219121223200_ljae098-B28","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1111\/bjd.21798","article-title":"Factors associated with treatment satisfaction in patients with hidradenitis suppurativa: results from the Global VOICE project","volume":"187","author":"Midgette","year":"2022","journal-title":"Br J Dermatol"},{"key":"2024102219121223200_ljae098-B29","doi-asserted-by":"crossref","first-page":"e750\u20131","DOI":"10.1111\/jdv.16605","article-title":"Effectiveness of secukinumab in hidradenitis suppurativa: an open study (20 cases)","volume":"34","author":"Reguia\u00ef","year":"2020","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"2024102219121223200_ljae098-B30","doi-asserted-by":"crossref","first-page":"e441\u20132","DOI":"10.1111\/jdv.17178","article-title":"Effectiveness of secukinumab in the treatment of moderate-severe hidradenitis suppurativa: results from an Italian multicentric retrospective study in a real-life setting","volume":"35","author":"Ribero","year":"2021","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"2024102219121223200_ljae098-B31","doi-asserted-by":"crossref","first-page":"1524","DOI":"10.1016\/j.jaad.2020.02.005","article-title":"Secukinumab in the treatment of moderate to severe hidradenitis suppurativa: results of an open-label trial","volume":"82","author":"Casseres","year":"2020","journal-title":"J Am Acad Dermatol"},{"key":"2024102219121223200_ljae098-B32","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1016\/j.jaad.2019.11.068","article-title":"Association between hidradenitis suppurativa, depression, anxiety, and suicidality: a systematic review and meta-analysis","volume":"83","author":"Patel","year":"2020","journal-title":"J Am Acad Dermatol"},{"key":"2024102219121223200_ljae098-B33","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1111\/bjd.16093","article-title":"Towards global consensus on core outcomes for hidradenitis suppurativa research: an update from the HISTORIC consensus meetings I and II","volume":"178","author":"Thorlacius","year":"2018","journal-title":"Br J Dermatol"},{"key":"2024102219121223200_ljae098-B34","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1007\/s13555-023-00906-2","article-title":"Short-term effectiveness, safety, and potential predictors of response of secukinumab in patients with severe hidradenitis suppurativa refractory to biologic therapy: a multicenter observational retrospective study","volume":"13","author":"Fernandez-Crehuet","year":"2023","journal-title":"Dermatol Ther (Heidelb)"},{"key":"2024102219121223200_ljae098-B35","doi-asserted-by":"crossref","first-page":"1150","DOI":"10.1016\/j.jaad.2019.12.044","article-title":"Clinical response rates, placebo response rates, and significantly associated covariates are dependent on choice of outcome measure in hidradenitis suppurativa: a post hoc analysis of PIONEER 1 and 2 individual patient data","volume":"82","author":"Frew","year":"2020","journal-title":"J Am Acad Dermatol"}],"container-title":["British Journal of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/bjd\/advance-article-pdf\/doi\/10.1093\/bjd\/ljae098\/57384936\/ljae098.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/bjd\/article-pdf\/190\/6\/836\/59971950\/ljae098.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/bjd\/article-pdf\/190\/6\/836\/59971950\/ljae098.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,22]],"date-time":"2024-10-22T19:12:25Z","timestamp":1729624345000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/bjd\/article\/190\/6\/836\/7626729"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3,12]]},"references-count":35,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2024,3,12]]},"published-print":{"date-parts":[[2024,5,16]]}},"URL":"https:\/\/doi.org\/10.1093\/bjd\/ljae098","relation":{},"ISSN":["0007-0963","1365-2133"],"issn-type":[{"value":"0007-0963","type":"print"},{"value":"1365-2133","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024,6]]},"published":{"date-parts":[[2024,3,12]]}}}